FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.
5 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Executive appointment and license negotiation details emerge regarding the company's operations in the Middle East.1 source
FDA documents challenged Capricor's claims while the company remains listed on Nasdaq.1 source
Keep exploring
The entities involved
- FDA
-
Nasdaq
American fully electronic stock exchange
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Related events
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Argenex SE and Capricor Therapeutics were listed on the Nasdaq stock exchange and are competing in the biotech sector.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.